Amylyx Plans FDA Filing After GLP-1 Drug Hits Trial Goals in Rare Metabolic Condition

Amylyx Pharmaceuticals’ avexitide led to statistically significant and clinically meaningful reductions in hypoglycemic events in patients with post-bariatric hypoglycemia (PBH). This peptide drug, a GLP-1 antagonist, was acquired from Eiger BioPharmaceuticals in 2024. The post Amylyx Plans FDA Filing After GLP-1 Drug Hits Trial Goals in Rare Metabolic Condition appeared first on MedCity News.

Read More

What Geriatric Emergency Departments Do Differently

It had been a rough few months. Cynthia Tompkins was hospitalized in May for osteomyelitis — a bone infection — then spent six weeks in a rehabilitation facility. “It was a struggle,” she said. “I didn’t bounce back too well.” Tompkins returned to her home in San Diego, but she was still taking antibiotics, along…

Read More

The Rise of Consumer Diagnostics and Emerging Trends

Consumer diagnostics will be one of several discussions at the INVEST Digital Health conference focused on power shifting to the consumer in healthcare. The conference is scheduled for October 29 in Dallas at Pegasus Park, in partnership with Health Wildcatters. Click here to view the agenda and register. The post The Rise of Consumer Diagnostics…

Read More